GAR-936对耐万古霉素肠球菌、耐甲氧西林金黄色葡萄球菌和耐青霉素肺炎链球菌的体外活性。
In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
作者信息
Patel R, Rouse M S, Piper K E, Steckelberg J M
机构信息
Division of Infectious Diseases and Infectious Diseases Research Laboratory, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
出版信息
Diagn Microbiol Infect Dis. 2000 Nov;38(3):177-9. doi: 10.1016/s0732-8893(00)00193-0.
We report the activity of the new glycylcycline antimicrobial agent GAR-936 against 37 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes), 26 clinical isolates of methicillin-resistant S. aureus and 30 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci, methicillin-resistant S. aureus, and penicillin-resistant S. pneumoniae were inhibited by < or = 1, < or = 2, or < or = 0.25 microg/ml of GAR-936, respectively. Time kill experiments using vancomycin-resistant enterococci did not demonstrate synergy or antagonism between 2 microg/ml of GAR-936 and 0.25 microg/ml of quinupristin/dalfopristin.
我们报告了新型甘氨酰环素抗菌剂GAR-936对37株耐万古霉素肠球菌临床分离株（包括携带vanA、vanB、vanC-1和vanC-2/3基因的菌株）、26株耐甲氧西林金黄色葡萄球菌临床分离株和30株高水平耐青霉素肺炎链球菌临床分离株的活性。耐万古霉素肠球菌、耐甲氧西林金黄色葡萄球菌和耐青霉素肺炎链球菌的所有分离株分别被≤1、≤2或≤0.25μg/ml的GAR-936抑制。使用耐万古霉素肠球菌进行的时间杀菌实验未显示2μg/ml的GAR-936与0.25μg/ml的奎奴普丁/达福普汀之间存在协同或拮抗作用。
Zotero 插件